PDF(Pubmed)
Abstract：
OBJECTIVE: Although recent in vitro maturation (IVM) studies in pediatric patients have demonstrated successful retrieval and maturation of oocytes, the studies included only a small number of premenarchal patients. In the present study, we examined the potential use of oocyte retrieval and maturation for pediatric patients who undergo ovarian tissue cryopreservation (OTC).
METHODS: We retrospectively examined the clinical records of pediatric patients who underwent OTC at our institution between October 2015 and December 2022. Data on the age, primary disease, menstrual history, pre-procedure chemotherapy, anti-Müllerian hormone (AMH) level, number of oocytes collected ex vivo from ovarian tissue, and number of mature oocytes from IVM were examined.
RESULTS: Data of 60 pediatric patients (aged 1 to 17 years) were included for analysis. Oocytes were retrieved from 36 patients; the oocytes of 18 of these patients could be cryopreserved. The IVM rate was significantly lower in the premenarchal patients than in the postmenarchal patients. The number of mature oocytes retrieved from IVM was higher in the no-chemotherapy group than in the chemotherapy group. A significant positive correlation was observed between the AMH level and the IVM outcomes.
CONCLUSIONS: Oocyte retrieval and maturation in pediatric patients undergoing OTC is particularly useful in those not receiving chemotherapy. In patients receiving chemotherapy, the AMH level may be useful for predicting the IVM outcome. Activation of the oocyte maturation process in vivo in pediatric patients and better understanding of the major regulators of oocyte maturation are necessary to improve the utility of the IVM procedure.
METHODS: We retrospectively examined the clinical records of pediatric patients who underwent OTC at our institution between October 2015 and December 2022. Data on the age, primary disease, menstrual history, pre-procedure chemotherapy, anti-Müllerian hormone (AMH) level, number of oocytes collected ex vivo from ovarian tissue, and number of mature oocytes from IVM were examined.
RESULTS: Data of 60 pediatric patients (aged 1 to 17 years) were included for analysis. Oocytes were retrieved from 36 patients; the oocytes of 18 of these patients could be cryopreserved. The IVM rate was significantly lower in the premenarchal patients than in the postmenarchal patients. The number of mature oocytes retrieved from IVM was higher in the no-chemotherapy group than in the chemotherapy group. A significant positive correlation was observed between the AMH level and the IVM outcomes.
CONCLUSIONS: Oocyte retrieval and maturation in pediatric patients undergoing OTC is particularly useful in those not receiving chemotherapy. In patients receiving chemotherapy, the AMH level may be useful for predicting the IVM outcome. Activation of the oocyte maturation process in vivo in pediatric patients and better understanding of the major regulators of oocyte maturation are necessary to improve the utility of the IVM procedure.
摘要：
目的：尽管最近在儿科患者中进行的体外成熟（IVM）研究已经证明了卵母细胞的成功回收和成熟，这些研究仅包括少数初潮患者.在本研究中,我们研究了接受卵巢组织冷冻保存(OTC)的儿科患者的卵母细胞取出和成熟的潜在用途.
方法：我们回顾性检查了2015年10月至2022年12月在我们机构接受OTC的儿科患者的临床记录。关于年龄的数据，原发疾病,月经史,术前化疗,抗苗勒管激素(AMH)水平,从卵巢组织离体收集的卵母细胞数量，并检查了来自IVM的成熟卵母细胞的数量。
结果：纳入60名儿科患者（1-17岁）的数据进行分析。从36例患者中取出卵母细胞；其中18例患者的卵母细胞可以冷冻保存。初潮前患者的IVM发生率明显低于初潮后患者。未化疗组从IVM回收的成熟卵母细胞数量高于化疗组。在AMH水平和IVM结果之间观察到显著正相关。
结论：接受OTC的儿科患者的卵母细胞提取和成熟在未接受化疗的患者中特别有用。在接受化疗的患者中，AMH水平可能有助于预测IVM结局.在儿科患者体内激活卵母细胞成熟过程以及更好地了解卵母细胞成熟的主要调节因子对于提高IVM程序的实用性是必要的。
方法：我们回顾性检查了2015年10月至2022年12月在我们机构接受OTC的儿科患者的临床记录。关于年龄的数据，原发疾病,月经史,术前化疗,抗苗勒管激素(AMH)水平,从卵巢组织离体收集的卵母细胞数量，并检查了来自IVM的成熟卵母细胞的数量。
结果：纳入60名儿科患者（1-17岁）的数据进行分析。从36例患者中取出卵母细胞；其中18例患者的卵母细胞可以冷冻保存。初潮前患者的IVM发生率明显低于初潮后患者。未化疗组从IVM回收的成熟卵母细胞数量高于化疗组。在AMH水平和IVM结果之间观察到显著正相关。
结论：接受OTC的儿科患者的卵母细胞提取和成熟在未接受化疗的患者中特别有用。在接受化疗的患者中，AMH水平可能有助于预测IVM结局.在儿科患者体内激活卵母细胞成熟过程以及更好地了解卵母细胞成熟的主要调节因子对于提高IVM程序的实用性是必要的。
